-transparent.png){kind=logo}
Twelve patients aged 53 to 89 years with presenile or senile dementia of the Alzheimer's type participated in a treatment trial of oral physostigmine. Patients first received the drug during an open dose-finding phase. In a double-blind crossover design phase, the patients' memory performance during treatment with an optimal memory-enhancing dose was compared with memory performance during placebo treatment. Response to medication was assessed by the Delayed Recognition Span Test, the Selective Reminding Test, and the Alzheimer's Disease Assessment Scale. Intergroup differences in response to physostigmine were nonsignificant. Age at onset of the disease did not differentiate partial responders from nonresponders.
M A Jenike, and
M S Albert, and
H Heller, and
J Gunther, and
D Goff
May 1999,
Pharmacopsychiatry,
M A Jenike, and
M S Albert, and
H Heller, and
J Gunther, and
D Goff
January 2012,
PloS one,
M A Jenike, and
M S Albert, and
H Heller, and
J Gunther, and
D Goff
February 1985,
Acta psychiatrica Scandinavica,
M A Jenike, and
M S Albert, and
H Heller, and
J Gunther, and
D Goff
March 2004,
Neurology,
M A Jenike, and
M S Albert, and
H Heller, and
J Gunther, and
D Goff
December 2005,
International journal of geriatric psychiatry,
M A Jenike, and
M S Albert, and
H Heller, and
J Gunther, and
D Goff
January 1990,
Current medical research and opinion,
M A Jenike, and
M S Albert, and
H Heller, and
J Gunther, and
D Goff
May 1996,
Progress in neuro-psychopharmacology & biological psychiatry,
M A Jenike, and
M S Albert, and
H Heller, and
J Gunther, and
D Goff
January 1989,
Progress in clinical and biological research,
M A Jenike, and
M S Albert, and
H Heller, and
J Gunther, and
D Goff
December 2005,
Current Alzheimer research,
M A Jenike, and
M S Albert, and
H Heller, and
J Gunther, and
D Goff
October 1988,
The Journal of clinical psychiatry,
